MCID: ALL006
MIFTS: 61

Allergic Asthma

Categories: Immune diseases, Respiratory diseases

Aliases & Classifications for Allergic Asthma

MalaCards integrated aliases for Allergic Asthma:

Name: Allergic Asthma 12 25 15 73
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Atopic Asthma, Susceptibility to 6
Ige-Mediated Allergic Asthma 73
Extrinsic Asthma 25
Asthma Allergic 55
Atopic Asthma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9415
ICD10 33 J45
ICD9CM 35 493.0
SNOMED-CT 68 16862005

Summaries for Allergic Asthma

Genetics Home Reference : 25 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder.

MalaCards based summary : Allergic Asthma, also known as extrinsic asthma with acute exacerbation, is related to aspergillosis and ige responsiveness, atopic, and has symptoms including wheezing, coughing and chest tightness. An important gene associated with Allergic Asthma is MS4A2 (Membrane Spanning 4-Domains A2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Fluticasone have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and skin, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 32.3 CCL17 IFNG IL10 IL4 IL5
2 ige responsiveness, atopic 31.8 IFNG IGHE IL10 IL13 IL4 IL4R
3 rhinitis 30.8 CCL11 CCL5 IGHE IL13 IL4 IL4R
4 allergic bronchopulmonary aspergillosis 30.7 CCL17 IL4 IL5
5 allergic rhinitis 30.3 CCL11 IFNG IGHE IL10 IL13 IL4
6 chlamydia 30.3 IFNG IL10 IL4
7 pollen allergy 30.2 IL13 IL4R IL5 RNASE3
8 rheumatoid arthritis 30.2 CCL5 IFNG IL10 IL17A IL4
9 intrinsic asthma 30.1 IL4 IL5 RNASE3
10 respiratory syncytial virus infectious disease 30.1 CCL5 IL13 IL5
11 esophagitis 30.0 CCL11 IL13 IL5 TSLP
12 pulmonary eosinophilia 30.0 CCL11 CCL17 CCL5 IL13 IL4 IL5
13 eosinophilic gastroenteritis 30.0 CCL11 IL5 RNASE3 TSLP
14 common variable immunodeficiency 29.9 IFNG IL10 IL4 IL5
15 bronchitis 29.9 CCL11 IL5 RNASE3
16 contact dermatitis 29.9 CCL17 IFNG IL10 IL4 IL5
17 allergic conjunctivitis 29.8 CCL11 IFNG IL13 IL4 IL5 RNASE3
18 esophagitis, eosinophilic, 1 29.8 CCL11 IL13 IL5 STAT6 TSLP
19 vernal keratoconjunctivitis 29.8 CCL11 CCL5 IL13 IL4 IL5 RNASE3
20 food allergy 29.8 IFNG IL10 IL13 IL4 IL5 MS4A2
21 dermatitis 29.8 CCL11 CCL17 IFNG IGHE IL13 IL17A
22 gastroenteritis 29.8 CCL11 IL10 IL4 IL5 RNASE3 TSLP
23 hypereosinophilic syndrome 29.7 CCL11 CCL17 IGHE IL13 IL4 IL5
24 keratoconjunctivitis 29.7 CCL11 CCL17 IFNG IL13 IL4 IL5
25 conjunctivitis 29.7 CCL11 IFNG IL13 IL4 IL5 MS4A2
26 asthma 29.6 ADAM33 CCL11 CCL17 CCL5 GATA3 IFNG
27 pulmonary disease, chronic obstructive 29.4 ADAM33 CCL11 CCL5 IL13 IL17A RNASE3
28 dermatitis, atopic 28.5 CCL11 CCL17 CCL5 GATA3 IFNG IGHE
29 hexamethylene diisocyanate allergic asthma 12.5
30 diphenylmethane-4,4'-diisocyanate allergic asthma 12.4
31 toluene meta-diisocyanate allergic asthma 12.4
32 methyl isocyanate allergic asthma 12.4
33 nickel allergic asthma 12.4
34 trimellitic anhydride allergic asthma 12.4
35 maleic anhydride allergic asthma 12.4
36 hexahydrophthalic anhydride allergic asthma 12.4
37 cobalt allergic asthma 12.4
38 isocyanates allergic asthma 12.4
39 phthalic anhydride allergic asthma 12.4
40 tetrachlorophthalic anhydride allergic asthma 12.4
41 toluene 2,4-diisocyanate allergic asthma 12.4
42 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL13 IL5
43 staphylococcal toxic shock syndrome 10.4 IFNG IGHE
44 b-cell growth factor 10.4 IFNG IL4
45 autoimmune myocarditis 10.4 IFNG IL4
46 chronic meningitis 10.4 CCL11 IL5
47 ascaridiasis 10.4 IL10 IL13
48 tungiasis 10.4 IL10 IL4
49 sporotrichosis 10.3 IFNG IL10
50 scabies 10.3 CCL11 IL10

Graphical network of the top 20 diseases related to Allergic Asthma:



Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma

Symptoms:

12
  • wheezing
  • coughing
  • chest tightness
  • shortness of breath or has_symptom rapid breathing

MGI Mouse Phenotypes related to Allergic Asthma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 CCL11 CCL17 CCL5 GATA3 IFNG IL10
2 immune system MP:0005387 10.19 CCL11 CCL17 CCL5 GATA3 IFNG IL10
3 digestive/alimentary MP:0005381 10.13 GATA3 IFNG IL10 IL13 IL17A IL4
4 homeostasis/metabolism MP:0005376 10.1 GATA3 IFNG IL10 IL13 IL17A IL4
5 endocrine/exocrine gland MP:0005379 10.06 GATA3 IFNG IL10 IL13 IL17A IL4
6 integument MP:0010771 9.76 GATA3 IFNG IL10 IL13 IL4 IL4R
7 no phenotypic analysis MP:0003012 9.5 ADAM33 GATA3 IFNG IL10 IL13 IL17A
8 respiratory system MP:0005388 9.36 CCL11 IFNG IL10 IL13 IL17A IL4

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 242138-07-4
2
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90566-53-3 62924
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6, 75614-87-8 774
4
Montelukast Approved Phase 4,Phase 3,Phase 2,Not Applicable 158966-92-8 5281040
5
Norepinephrine Approved Phase 4 51-41-2 439260
6
Terbutaline Approved Phase 4 23031-25-6 5403
7
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 10102-43-9 145068
8
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
9
Theophylline Approved Phase 4 58-55-9 2153
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
11
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
12
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 63006 5281004
13
mometasone furoate Approved, Vet_approved Phase 4,Phase 3,Phase 2 83919-23-7
14
Metronidazole Approved Phase 4 443-48-1 4173
15
Vancomycin Approved Phase 4 1404-90-6 14969 441141
16
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
17
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
18 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
23 Anti-Allergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33
Histamine Phosphate Phase 4,Phase 3,Phase 2,Not Applicable 51-74-1 65513
34 Leukotriene Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Formoterol Fumarate Phase 4,Phase 2,Phase 3
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable
41 Immunoglobulin E Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Vasoconstrictor Agents Phase 4
43 Adrenergic alpha-Agonists Phase 4
44 Albuterol Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Sympathomimetics Phase 4,Phase 3,Not Applicable
46 Tocolytic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Acidophilus Phase 4
48 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
49 Viscosupplements Phase 4
50 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
2 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
3 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
4 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4 Omalizumab;Placebo
5 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4 omalizumab at a dose of 0.016mg/kg/IU/mL;Placebo
6 Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
7 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
8 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed NCT00264849 Phase 4 Omalizumab
9 Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy Completed NCT00329381 Phase 4 Xolair;Xolair
10 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
11 Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Completed NCT00490425 Phase 4 Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
12 Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen Completed NCT00518518 Phase 4 Staloral 300;placebo
13 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
14 Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
15 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils Completed NCT02023151 Phase 4 Omalizumab
16 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed NCT01125748 Phase 4 Omalizumab;Placebo;Asthma therapies
17 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma Completed NCT00980707 Phase 4 Inhaled corticosteroid (fluticasone)
18 Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Completed NCT00492076 Phase 4
19 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
20 Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
21 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) Completed NCT01922037 Phase 4 Omalizumab
22 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed NCT00454051 Phase 4 Omalizumab;placebo
23 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
24 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
25 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
26 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
27 The Effect of Xolair (Omalizumab) on Allergy Blood Cells Completed NCT00657891 Phase 4 Omalizumab;Placebo
28 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
29 C1-inhibitor in Allergic ASThma Patients Recruiting NCT03051698 Phase 4 C1-inhibitor;Antibiotics
30 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) Terminated NCT00070707 Phase 4 Nasonex
31 No Resistance After Long Term Treatment SERETIDE Withdrawn NCT00456313 Phase 4 FLIXOTIDE and SERETIDE
32 A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma Withdrawn NCT00242359 Phase 4 omalizumab
33 Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations Unknown status NCT01520051 Phase 3 Mepolizumab;Placebo
34 Omalizumab in Non-atopic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
35 Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma Completed NCT01976208 Phase 2, Phase 3 Omalizumab;placebo
36 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy Completed NCT01202903 Phase 3 Omalizumab;Placebo
37 Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis Completed NCT00396409 Phase 3 Depigoid;Omalizumab;Placebo
38 Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Completed NCT00829179 Phase 3 RhuMab-E25
39 Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children Completed NCT01328886 Phase 3 Omalizumab
40 Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma Completed NCT00482248 Phase 3 Omalizumab
41 A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma Completed NCT00109200 Phase 3 Xolair (omalizumab)
42 Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma Completed NCT00986323 Phase 3
43 Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) Completed NCT01155700 Phase 3 omalizumab
44 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma Completed NCT00079937 Phase 3 Omalizumab;Placebo;Fluticasone
45 Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. Completed NCT00500539 Phase 3 omalizumab
46 Fish Oil and Asthma in House Dust Mite Allergy Completed NCT00380926 Phase 2, Phase 3 polyunsatturated fatty acids (fish oil)
47 A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Completed NCT02596321 Phase 3 Mitizax;Placebo
48 Efficacy Of Bacterial Lysate In Asthmatic Children Completed NCT02541331 Phase 3
49 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED) Completed NCT00289874 Phase 3 montelukast sodium;Comparator: Placebo
50 Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients Completed NCT00482508 Phase 3 Omalizumab

Search NIH Clinical Center for Allergic Asthma

Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

41
Lung, T Cells, Skin, Bone, Testes, Neutrophil, B Cells

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 1232)
# Title Authors Year
1
Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma. ( 29881388 )
2018
2
The effects of bone marrow-derived mesenchymal stem cells on ovalbumin-induced allergic asthma and cytokine responses in mice. ( 29922428 )
2018
3
Advances and Evolving Concepts in Allergic Asthma. ( 29427987 )
2018
4
Expansion of a CD26<sup>low</sup>effector TH subset and reduction of circulating levels of sCD26 in stable allergic asthma in adults. ( 29297467 )
2018
5
Dexamethasone alleviates allergic asthma immature rat through Toll like receptor 4. ( 29364486 )
2018
6
Modeling Unobserved Heterogeneity in Susceptibility to Ambient Benzo[a]pyrene Concentration among Children with Allergic Asthma Using an Unsupervised Learning Algorithm. ( 29320438 )
2018
7
Does adiposity mediate the relationship between socioeconomic position and non-allergic asthma in childhood? ( 29367283 )
2018
8
Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? ( 29879991 )
2018
9
Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyperresponsiveness in grass pollen mouse models for allergic asthma. ( 29752757 )
2018
10
Subcutaneous allergen immunotherapy may be a suitable treatment for exacerbator allergic asthma. ( 29803710 )
2018
11
Developmental endothelial locus-1 (Del-1) antagonizes Interleukin-17-mediated allergic asthma. ( 29437247 )
2018
12
March1 E3 Ubiquitin Ligase Modulates Features of Allergic Asthma in an Ovalbumin-Induced Mouse Model of Lung Inflammation. ( 29854835 )
2018
13
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
14
Intranasal administration of probiotic Lactobacillus rhamnosus GG prevents birch pollen-induced allergic asthma in a murine model. ( 29888398 )
2018
15
Allergic asthma is associated with increased risk of infections requiring antibiotics. ( 29413341 )
2018
16
Role of neutrophils in allergic asthma. ( 29883877 )
2018
17
Long Sun-Exposures Influencing High Sub-Cutaneous Synthesis of Vitamin-D3 may be Associated with Exacerbation of Symptoms in Allergic-Asthma. ( 29755960 )
2018
18
Initial Influenza Virus Replication Can Be Limited in Allergic Asthma Through Rapid Induction of Type III Interferons in Respiratory Epithelium. ( 29867963 )
2018
19
Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. ( 29318574 )
2018
20
Author Correction: A gammaherpesvirus provides protection against allergic asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes. ( 29955109 )
2018
21
Immune Homeostasis: Effects of Chinese Herbal Formulae and Herb-Derived Compounds on Allergic Asthma in Different Experimental Models. ( 29752613 )
2018
22
Activated Leukocyte Cell Adhesion Molecule Stimulates the T Cell Response in Allergic Asthma. ( 29394080 )
2018
23
Dephosphorylated Polymerase I and Transcript Release Factor Prevents Allergic Asthma Exacerbations by Limiting IL-33 Release. ( 29977243 )
2018
24
5-BDBD ameliorates an OVA-induced allergic asthma by the reduction of Th2 cytokines production. ( 29796218 )
2018
25
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. ( 29422778 )
2018
26
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma. ( 29319845 )
2018
27
Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab? ( 29741411 )
2018
28
Increased Susceptibility to Allergic Asthma with the Impairment of Respiratory Tolerance Caused by Psychological Stress. ( 29874662 )
2018
29
Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab. ( 29300536 )
2018
30
Biased Generation and In Situ Activation of Lung Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. ( 29343554 )
2018
31
Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. ( 29977648 )
2018
32
Can natural killer cells represent an early life immune response in development of allergic asthma? More precise data analysis should be considered. ( 29945813 )
2018
33
Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. ( 29302700 )
2018
34
Hypergravity enhances the therapeutic effect of dexamethasone in allergic asthma and rhinitis animal model. ( 29772010 )
2018
35
Circulating CXCR5+CD4+ T cells participate in the IgE accumulation in allergic asthma. ( 29518454 )
2018
36
Feishu Acupuncture Inhibits Acetylcholine Synthesis and Restores Muscarinic Acetylcholine Receptor M2 Expression in the Lung When Treating Allergic Asthma. ( 29520557 )
2018
37
Propofol Attenuates Airway Inflammation in a Mast Cell-Dependent Mouse Model of Allergic Asthma by Inhibiting the Toll-like Receptor 4/Reactive Oxygen Species/Nuclear Factor κB Signaling Pathway. ( 29532264 )
2018
38
Is suicidal ideation associated with allergic asthma and allergic rhinitis? ( 29538540 )
2018
39
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. ( 29545284 )
2018
40
Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. ( 29548318 )
2018
41
Impact of allergen immunotherapy in allergic asthma. ( 29569506 )
2018
42
Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma. ( 29569508 )
2018
43
FcγRIIIA Negatively Impacts Humoral Immune Responses but Not Overall Lung Inflammation in an Ovalbumin-Induced Allergic Asthma Mouse Model. ( 29597194 )
2018
44
Pulmonary neuroendocrine cells amplify allergic asthma responses. ( 29599193 )
2018
45
PTEN gene silencing contributes to airway remodeling and induces airway smooth muscle cell proliferation in mice with allergic asthma. ( 29600050 )
2018
46
Doxycycline suppresses Chlamydia pneumoniae induced interferon-gamma responses in peripheral blood mononuclear cells in children with allergic asthma. ( 29615379 )
2018
47
House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. ( 29642713 )
2018
48
Effects of anthraquinones from Cassia occidentalis L. on ovalbumin-induced airways inflammation in a mouse model of allergic asthma. ( 29649507 )
2018
49
Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma. ( 29665659 )
2018
50
Aryl hydrocarbon receptor activation by diesel exhaust particles mediates epithelium-derived cytokines expression in severe allergic asthma. ( 29672862 )
2018

Variations for Allergic Asthma

ClinVar genetic disease variations for Allergic Asthma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MS4A2 NM_000139.4(MS4A2): c.710A> G (p.Glu237Gly) single nucleotide variant risk factor rs569108 GRCh37 Chromosome 11, 59863104: 59863104
2 MS4A2 NM_000139.4(MS4A2): c.710A> G (p.Glu237Gly) single nucleotide variant risk factor rs569108 GRCh38 Chromosome 11, 60095631: 60095631

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 CCL11 CCL5 GATA3 IFNG IGHE IL10
2
Show member pathways
13.88 CCL11 CCL17 CCL5 IL10 IL13 IL17A
3
Show member pathways
13.75 CCL11 CCL17 CCL5 IFNG IL10 IL13
4
Show member pathways
13.61 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Show member pathways
13.48 CCL11 CCL17 CCL5 IL10 IL13 IL17A
6
Show member pathways
13.43 CCL11 CCL5 GATA3 IFNG IGHE IL10
7
Show member pathways
13.38 CCL11 CCL17 CCL5 IL10 IL13 IL17A
8
Show member pathways
12.95 CCL11 IFNG IL10 IL13 IL17A IL4
9 12.86 IFNG IL13 IL4 IL4R IL5 STAT6
10
Show member pathways
12.73 IFNG IGHE IL10 IL4 IL4R ITK
11
Show member pathways
12.72 GATA3 IFNG IL10 IL13 IL17A IL4
12 12.68 CCL5 GATA3 IFNG IL10 IL17A IL4
13
Show member pathways
12.66 IGHE IL13 IL4 IL5 ITK MS4A2
14
Show member pathways
12.55 GATA3 IFNG IL10 IL17A IL4 IL5
15
Show member pathways
12.51 IFNG IL10 IL13 IL4 IL4R IL5
16
Show member pathways
12.5 CCL11 GATA3 IGHE IL4 IL4R STAT6
17
Show member pathways
12.46 CCL11 CCL17 IFNG IL13 IL17A IL4
18
Show member pathways
12.37 IFNG IL10 IL13 IL17A IL4 IL5
19
Show member pathways
12.16 CCL11 CCL17 CCL5 IFNG IL10 IL13
20
Show member pathways
12.09 GATA3 IFNG IL10 IL17A
21 12.03 CCL11 GATA3 IGHE IL10 IL13 IL17A
22 12.02 IFNG IL10 IL4 IL5
23 11.93 GATA3 IFNG IL13 IL4 IL5
24 11.91 IFNG IL10 IL4R STAT6
25 11.85 IL4 IL4R IL5
26
Show member pathways
11.84 GATA3 IFNG IL4 IL5
27 11.82 CCL11 CCL17 CCL5 IFNG IL10 IL13
28 11.81 CCL5 IFNG IL17A
29 11.8 CCL11 CCL5 IL13 IL4 IL5
30 11.74 GATA3 IL10 IL5
31 11.66 CCL11 CCL17 IGHE IL10 IL4 IL4R
32 11.64 CCL5 IL10 IL13 IL4
33 11.56 CCL11 CCL17 GATA3 IFNG IL10 IL13
34 11.52 CCL11 STAT6 TSLP
35 11.51 GATA3 IFNG IL10 IL13 IL17A IL4
36 11.46 IFNG IL4 IL4R IL5
37 11.41 IFNG IL10 IL13 IL4 IL5
38 11.37 IFNG IL10 IL13 IL4 IL5 IL9
39 11.34 CCL11 CCL17 CCL5 IL10 IL13 IL17A
40 11.13 CCL11 CCL17 CCL5 IL10 IL13 IL17A
41 10.73 GATA3 IFNG IL13 IL17A IL4 IL5

GO Terms for Allergic Asthma

Cellular components related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CCL11 CCL17 CCL5 IFNG IGHE IL10
2 extracellular space GO:0005615 9.44 CCL11 CCL17 CCL5 IFNG IL10 IL13

Biological processes related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.91 CCL11 CCL17 CCL5 IL10 IL13 IL17A
2 regulation of signaling receptor activity GO:0010469 9.9 CCL11 CCL17 CCL5 IFNG IL10 IL13
3 cellular response to tumor necrosis factor GO:0071356 9.85 CCL11 CCL17 CCL5 GATA3
4 cellular response to interferon-gamma GO:0071346 9.82 CCL11 CCL17 CCL5
5 neutrophil chemotaxis GO:0030593 9.81 CCL11 CCL17 CCL5
6 chemokine-mediated signaling pathway GO:0070098 9.81 CCL11 CCL17 CCL5
7 response to virus GO:0009615 9.8 CCL11 CCL5 GATA3 IFNG
8 positive regulation of cold-induced thermogenesis GO:0120162 9.78 IL13 IL4 IL4R STAT6
9 monocyte chemotaxis GO:0002548 9.77 CCL11 CCL17 CCL5
10 cellular response to interleukin-1 GO:0071347 9.76 CCL11 CCL17 CCL5 IL17A
11 positive regulation of B cell proliferation GO:0030890 9.73 IL13 IL4 IL5
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 CCL5 IFNG IL13 IL4 TSLP
13 lymphocyte chemotaxis GO:0048247 9.71 CCL11 CCL17 CCL5
14 cytokine-mediated signaling pathway GO:0019221 9.7 CCL11 CCL5 GATA3 IGHE IL10 IL13
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 GATA3 IL10 IL13 IL4
16 positive regulation of mast cell degranulation GO:0043306 9.63 IL13 IL4R
17 positive regulation of immunoglobulin production GO:0002639 9.62 IL13 IL4R
18 positive regulation of interleukin-5 production GO:0032754 9.62 GATA3 TSLP
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IL4
20 positive regulation of interleukin-5 secretion GO:2000664 9.61 GATA3 TSLP
21 positive regulation of macrophage activation GO:0043032 9.61 IL10 IL13 IL4R
22 positive regulation of interleukin-23 production GO:0032747 9.6 IFNG IL17A
23 interleukin-4-mediated signaling pathway GO:0035771 9.58 IL4R STAT6
24 regulation of isotype switching GO:0045191 9.58 IL10 IL4
25 positive regulation of interleukin-13 production GO:0032736 9.58 GATA3 IL4 TSLP
26 type 2 immune response GO:0042092 9.57 IL10 IL4
27 negative regulation of complement-dependent cytotoxicity GO:1903660 9.52 IL13 IL4
28 positive regulation of isotype switching to IgE isotypes GO:0048295 9.51 IL4 STAT6
29 immune response GO:0006955 9.44 CCL11 CCL17 CCL5 IFNG IGHE IL10

Molecular functions related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 IL10 IL4 IL5 IL9
2 chemokine activity GO:0008009 9.54 CCL11 CCL17 CCL5
3 CCR chemokine receptor binding GO:0048020 9.43 CCL11 CCL17 CCL5
4 cytokine activity GO:0005125 9.36 CCL11 CCL17 CCL5 IFNG IL10 IL13
5 cytokine receptor binding GO:0005126 9.33 IL13 IL4 IL9
6 CCR4 chemokine receptor binding GO:0031729 8.96 CCL17 CCL5

Sources for Allergic Asthma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....